

[Sign In](#) | [Register](#)[Home](#) | [News](#) | [Get involved](#) | [About NICE](#)

[Home](#) > [About NICE](#) > [How we work](#) > [Patient access schemes liaison unit \(PASLU\)](#) >
 List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS.

List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS.

TA Ref	Treatment	Indication	Company	Type
TA185	Trabectedin (Yondelis)	Advanced soft tissue sarcoma	PharmaMar	Dose cap
TA155	Ranibizumab (Lucentis)	Macular degeneration (Acute wet AMD)	Novartis	Simple discount
TA171	Lenalidomide (Revlimid)	Multiple myeloma	Celgene	Dose cap
TA162	Erlotinib (Tarceva)	Non small cell lung cancer	Roche	Simple discount
TA129	Bortezomib (Velcade)	Multiple myeloma	JC	Response scheme
TA180	Ustekinumab (Stelera)	Moderate to severe psoriasis	J&J / JC	Free stock
TA179	Sunitinib (Sutent)	Gastrointestinal stromal tumour	Pfizer	Free stock
TA176	Cetuximab (Erbix)	Metastatic colorectal cancer (first Line)	Merck S.	Rebate
TA169	Sunitinib (Sutent)	Renal cell carcinoma	Pfizer	Free stock
TA186	Certolizumab pegol (Cimzia)	Rheumatoid arthritis	UCB	Free initial stock
TA192	Gefitinib (Iressa)	Non small cell lung cancer	Astra Zeneca	Single fixed price

TA215	Pazopanib (Votrient)	Advanced renal cell carcinoma	GSK	Discount+ poss rebate
TA218	Azacitidine (Vidaza)	Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia	Celgene	Simple discount
TA220	Golimumab (Simponi)	Psoriatic arthritis	Merck Sharp & Dohme	Free stock
TA221	Romiplostim (Nplate)	Chronic idiopathic (immune) thrombocytopenic purpura	Amgen	Simple discount
TA225	Golimumab (Simponi)	Rheumatoid arthritis	Merck Sharp & Dohme	Free stock
TA233	Golimumab (Simponi)	Ankylosing spondylitis	Merck Sharp & Dohme	Free stock
TA235	Mifamurtide (Mepact)	High grade resectable non-metastatic osteosarcoma	Takeda	Simple discount
TA238	Tocilizumab (RoActemra)	Systemic juvenile idiopathic arthritis	Roche	Simple discount
TA241	Nilotinib (Tasigna)	Imatinib-resistant chronic myeloid leukaemia	Novartis	Simple discount
TA247	Tocilizumab (RoActemra)	Rheumatoid arthritis	Roche	Simple discount
TA251	Nilotinib (Tasigna)	First-line treatment of chronic myeloid leukaemia	Novartis	Simple discount
TA254	Fingolimod (Gilenya)	Highly active relapsing-remitting multiple sclerosis	Novartis	Simple discount
TA258	Erlotinib (Tarceva)	First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	Roche	Simple discount
TA259	Abiraterone acetate (Zytiga)	Castration-resistant metastatic prostate cancer previously treated with a docetaxel containing regimen	Janssen-Cilag	Simple discount

Explore NICE	Evidence Search
NICE Community	

TA265	Denosumab (Xgeva)	Skeletal related events in adults with bone metastases from solid tumours	Amgen	Simple discount
TA268	Ipilimumab (Yervoy)	Advanced melanoma, 2 nd Line	Bristol-Myers Squibb	Simple discount
TA269	Vemurafenib (Zelboraf)	Metastatic mutation positive melanoma	Roche	Simple discount
TA274	Ranibizumab (Lucentis)	Diabetic macular odema	Novartis	Simple discount
TA276	Colistimethate (Colobreathe)	Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis	Forest Laboratories UK	Simple discount
TA276	Tobramycin (TOBI Podhaler)	Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis	Novartis	Simple discount
TA278	Omalizumab (Xolair)	Severe persistent asthma	Novartis	Simple discount
TA280	Abatacept (Orencia)	Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis	Bristol-Myers Squibb	Simple discount
TA282	Pirfenidone (Esbriet)	Mild to moderate idiopathic pulmonary fibrosis	Intermune	Simple discount

This page was last updated: 14 May 2013

About NICE

Who we are, What we do, How we work

Get Involved

Current Consultations, Join a working group

Scientific Advice Consultancy

Advice to pharmaceutical companies

Quality Initiatives

Clinical commissioning group outcomes indicator set, Quality and Outcomes Framework, NICE fellows and scholars

NICE International

NICE International Advisory group, International projects

NICE accreditation

What's new in accreditation, accreditation decisions

Cost saving support

NICE Guidance

Find Guidance, Clinical Guidelines, Diagnostics, Interventional Procedures, Medical Technologies, Public Health, Quality Standards, Social care, Technology Appraisals

NICE Quality Standards

Published quality standards, Quality standards in development, Social care quality standards

Research and development

Research recommendations

Search, Latest recommendations

Patients and the public
Search guidance, Treatment and care,
Join a working group

Other publications
Special reports and HDA publications

Social care

Support for General Practice
Resources for GPs, NICE
Commissioning resources

Commissioning guides
Commissioning guides for
Cardiovascular, Central nervous
system, Digestive system

Putting guidance into practice
Benefits, Implementation tools, How to
guides, Assessment tools, Help
implement NICE Guidance ...

Education and learning
Education, Strategy, Online tools

Shared learning
Shared learning implementation
guidance

Notify NICE
New and reviewed Interventional
procedures

Medicines and prescribing support
Evidence summaries: new medicines,
Events, Alerts

News and press
NICE press Office, News and features,
Press releases, Latest News